CLINICAL TRIALS PROFILE FOR COBICISTAT; ELVITEGRAVIR; EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE

All Clinical Trials for COBICISTAT; ELVITEGRAVIR; EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT01497899 ↗	Safety and Efficacy of E/C/F/TAF (Genvoya®) Versus E/C/F/TDF (Stribild®) in HIV-1 Infected, Antiretroviral Treatment-Naive Adults	Completed	Gilead Sciences	Phase 2	2011-12-28	The primary objective of this study is to evaluate the efficacy of elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (Genvoya®; E/C/F/TAF) fixed-dose combination (FDC) versus elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate (Stribild®; E/C/F/TDF) FDC in HIV-1 infected, antiretroviral treatment-naive adults.
NCT01780506 ↗	Study to Evaluate the Safety and Efficacy of E/C/F/TAF (Genvoya®) Versus E/C/F/TDF (Stribild®) in HIV-1 Positive, Antiretroviral Treatment-Naive Adults	Completed	Gilead Sciences	Phase 3	2012-12-26	The primary objective of this study is to evaluate the efficacy of elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (E/C/F/TAF) fixed-dose combination (FDC) versus elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate (E/C/F/TDF) FDC in HIV-1 positive, antiretroviral treatment-naive adults.
NCT01797445 ↗	Study to Evaluate the Safety and Efficacy of E/C/F/TAF Versus E/C/F/TDF in HIV-1 Positive, Antiretroviral Treatment-Naive Adults	Completed	Gilead Sciences	Phase 3	2013-03-12	The primary objective of this study is to evaluate the efficacy of elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (E/C/F/TAF) fixed-dose combination (FDC) versus elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate (E/C/F/TDF) in HIV-1 positive, antiretroviral treatment-naive adults.
NCT02251236 ↗	Elvitegravir (EVG) Cerebrospinal Fluid (CSF) Pharmacokinetics in HIV-Infected Individuals	Completed	Gilead Sciences	N/A	2016-01-01	The project will have two tracks, one for participants who are currently taking elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate or E/C/F/tenofovir alafenamide (E/C/F/TDF or E/C/F/TAF) single-tablet regimen* (STR) (Track A) and one for participants who will begin therapy with E/C/F/TDF or E/C/F/TAF STR during the study (Track B). Participants will take E/C/F/TDF and/or E/C/F/tenofovir alafenamide fumarate (E/C/F/TAF) STR** (if available) for 24 weeks. *Co-formulation of 150 mg of elvitegravir, 150 mg of cobicistat, 200 mg of emtricitabine, and 300 mg of tenofovir disoproxil fumarate. **Co-formulation of 150 mg of elvitegravir, 150 mg of cobicistat, 200 mg of emtricitabine, and 10 mg of tenofovir alafenamide fumarate.
NCT02251236 ↗	Elvitegravir (EVG) Cerebrospinal Fluid (CSF) Pharmacokinetics in HIV-Infected Individuals	Completed	University at Buffalo	N/A	2016-01-01	The project will have two tracks, one for participants who are currently taking elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate or E/C/F/tenofovir alafenamide (E/C/F/TDF or E/C/F/TAF) single-tablet regimen* (STR) (Track A) and one for participants who will begin therapy with E/C/F/TDF or E/C/F/TAF STR during the study (Track B). Participants will take E/C/F/TDF and/or E/C/F/tenofovir alafenamide fumarate (E/C/F/TAF) STR** (if available) for 24 weeks. *Co-formulation of 150 mg of elvitegravir, 150 mg of cobicistat, 200 mg of emtricitabine, and 300 mg of tenofovir disoproxil fumarate. **Co-formulation of 150 mg of elvitegravir, 150 mg of cobicistat, 200 mg of emtricitabine, and 10 mg of tenofovir alafenamide fumarate.
NCT02251236 ↗	Elvitegravir (EVG) Cerebrospinal Fluid (CSF) Pharmacokinetics in HIV-Infected Individuals	Completed	University of California, San Diego	N/A	2016-01-01	The project will have two tracks, one for participants who are currently taking elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate or E/C/F/tenofovir alafenamide (E/C/F/TDF or E/C/F/TAF) single-tablet regimen* (STR) (Track A) and one for participants who will begin therapy with E/C/F/TDF or E/C/F/TAF STR during the study (Track B). Participants will take E/C/F/TDF and/or E/C/F/tenofovir alafenamide fumarate (E/C/F/TAF) STR** (if available) for 24 weeks. *Co-formulation of 150 mg of elvitegravir, 150 mg of cobicistat, 200 mg of emtricitabine, and 300 mg of tenofovir disoproxil fumarate. **Co-formulation of 150 mg of elvitegravir, 150 mg of cobicistat, 200 mg of emtricitabine, and 10 mg of tenofovir alafenamide fumarate.
NCT02616029 ↗	Study to Evaluate Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) Fixed Dose Combination (FDC) in Virologically-Suppressed HIV-1 Infected Adults Harboring the Archived Isolated NRTI Resistance Mutation M184V/M184	Completed	Gilead Sciences	Phase 3	2015-12-17	The primary objective of the study is to evaluate the efficacy of elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (E/C/F/TAF) fixed-dose combination (FDC) after switching from a stable regimen consisting of emtricitabine/tenofovir disoproxil fumarate (FTC/TDF) or abacavir/lamivudine (ABC/3TC) plus a third antiretroviral (ARV) agent in participants harboring the archived nucleoside/nucleotide reverse transcriptase inhibitor (NRTI) resistance mutation M184V and/or M184I in human immunodeficiency virus (HIV) -1 reverse transcriptase. This is a two part study. If the rate of virologic failure in Part 1 is deemed acceptable, once the internal data monitoring committee officially completes the interim review, the study will continue to Part 2.

Clinical Trial Conditions for COBICISTAT; ELVITEGRAVIR; EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE

Condition Name

Condition Name for COBICISTAT; ELVITEGRAVIR; EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE
Intervention	Trials
HIV-1 Infection	4
HIV	3
HIV Infections	3
HIV/AIDS	2

Condition MeSH

Condition MeSH for COBICISTAT; ELVITEGRAVIR; EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE
Intervention	Trials
HIV Infections	5
Acquired Immunodeficiency Syndrome	3
Hepatitis	1
Coinfection	1

Clinical Trial Locations for COBICISTAT; ELVITEGRAVIR; EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE

Trials by Country

Trials by Country for COBICISTAT; ELVITEGRAVIR; EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE
Location	Trials
United States	89
Switzerland	7
Canada	7
Italy	5
Spain	4

Trials by US State

Trials by US State for COBICISTAT; ELVITEGRAVIR; EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE
Location	Trials
California	7
Missouri	5
Georgia	5
Florida	5
Washington	4

Clinical Trial Progress for COBICISTAT; ELVITEGRAVIR; EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE

Clinical Trial Phase

Clinical Trial Phase for COBICISTAT; ELVITEGRAVIR; EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE
Clinical Trial Phase	Trials
Phase 3	6
Phase 2	2
Phase 1/Phase 2	1

Clinical Trial Status

Clinical Trial Status for COBICISTAT; ELVITEGRAVIR; EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE
Clinical Trial Phase	Trials
Completed	9
Recruiting	1
Withdrawn	1

Clinical Trial Sponsors for COBICISTAT; ELVITEGRAVIR; EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE

Sponsor Name

Sponsor Name for COBICISTAT; ELVITEGRAVIR; EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE
Sponsor	Trials
Gilead Sciences	10
University Hospital Inselspital, Berne	1
University of California, Los Angeles	1

Sponsor Type

Sponsor Type for COBICISTAT; ELVITEGRAVIR; EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE
Sponsor	Trials
Industry	11
Other	7

Clinical Trials Update, Market Analysis, and Projections for Cobicistat; Elvitegravir; Emtricitabine; Tenofovir Alafenamide Fumarate

Last updated: October 28, 2025

Introduction

The combination of Cobicistat, Elvitegravir, Emtricitabine, and Tenofovir Alafenamide Fumarate forms a cornerstone in antiretroviral therapy (ART) for human immunodeficiency virus (HIV) treatment. With ongoing developments in clinical trials, evolving market dynamics, and expanding global access, these agents collectively sustain significant commercial and therapeutic relevance. This report provides a comprehensive update on the latest clinical trials, analyzes current market trends, and projects future growth trajectories for these pivotal components of HIV pharmacotherapy.

Clinical Trials Update

Overview of Current Clinical Trials

Recent years have witnessed a robust pipeline of clinical studies examining the efficacy, safety, and regimen optimization involving the four agents:

• Cobicistat (a pharmacokinetic enhancer)
• Elvitegravir (an integrase strand transfer inhibitor)
• Emtricitabine (a nucleoside reverse transcriptase inhibitor)
• Tenofovir Alafenamide (TAF) (a nucleotide reverse transcriptase inhibitor)

Most notable are Phase III trials evaluating fixed-dose combinations (FDCs) for treatment-naïve and treatment-experienced populations, with a focus on safety profiles, resistance barriers, and long-term tolerability.

Recent and Ongoing Trials

1. Genvoya (elvitegravir/cobicistat/emtricitabine/TAF):
   Multiple Phase III trials continue to assess its efficacy as a once-daily regimen in diverse populations, including pregnant women and adolescents. Data indicate sustained viral suppression with improved renal and bone safety profiles compared to tenofovir disoproxil fumarate (TDF)-based regimens [1].

2. Efficacy in Special Populations:
   Trials extending to pediatric and pregnant cohorts are underway, validating fixed-dose combinations' safety and pharmacokinetics. Particularly, the IMPAACT P1026s study explores pediatric dosing, confirming that TAF-based regimens are well-tolerated in children older than two years [2].

3. Long-term Safety and Resistance Profiles:
   Ongoing studies evaluate resistance emergence, particularly with the integrase inhibitor Elvitegravir, when used in combination regimens. Results suggest a high barrier to resistance, though ongoing surveillance is essential for specific populations [3].

4. Novel Formulations and Combinations:
   Researchers are exploring alternative fixed-dose combinations that incorporate these agents with newer drugs to enhance adherence and minimize adverse events, with Phase II studies demonstrating promising initial results [4].

Emerging Data and Concerns

Recent trials have also scrutinized potential renal and mitochondrial toxicities associated with integrase inhibitors and nucleotides, especially in patients with comorbidities. While TAF demonstrates a favorable safety profile relative to TDF, vigilance remains pertinent [5].

Regulatory Developments

Regulatory agencies, notably the FDA and EMA, continue to approve and update prescribing information for Genvoya, Stribild (elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate), and other formulations. Recent approvals for pediatric use in select markets have broadened access [6].

Market Analysis

Market Size and Segmentation

The global HIV therapy market, valued at approximately $28 billion in 2022, is projected to expand at a CAGR of 4.2% through 2030, driven predominantly by the uptake of TAF-based regimens [7]. The agents in focus are central to this growth:

• Cobicistat and Elvitegravir: Incorporated predominantly in combination products; their sales account for a significant share of integrase inhibitors and pharmacokinetic enhancers.
• Emtricitabine and TAF: Core components in multiple branded and generic formulations, with TAF increasingly replacing TDF due to safety advantages.

Key Market Drivers

• Enhanced Safety Profile: TAF's superior renal and bone safety compared to TDF boosts adoption, especially in aging populations.
• Regulatory Approvals: Approvals for pediatric and other special populations expand market reach.
• Fixed-Dose Combinations (FDCs): Simplify regimens, improve adherence, and are preferred by clinicians and patients, increasing sales.
• Global Access Initiatives: WHO's inclusion of TAF-based regimens supports penetration in low- and middle-income countries (LMICs).

Competitive Landscape

Major players like Gilead Sciences (Genvoya, Biktarvy), ViiV Healthcare, and Merck dominate, investing heavily in R&D for next-generation formulations:

• Gilead's recent launches focus on expanding pediatric and long-acting formulations.
• ViiV progresses with trials on dual therapy regimens incorporating these agents.

Emerging generic manufacturers are increasingly entering markets in LMICs, exerting downward pressure on prices.

Market Challenges

• Pricing and Reimbursement: High costs of branded formulations remain barriers, though generic competition mitigates this in certain regions.
• Resistance Concerns: While resistance barriers are high, improper use or suboptimal adherence risk compromising long-term efficacy.
• Patient Adherence: Simplified, once-daily FDCs are critical; continued innovation remains necessary to tackle adherence issues.

Market Projections

Based on current trends, the following projections are made:

• Growth Trajectory: The HIT (HIV Integrated Treatment) segment containing these agents is expected to reach $35 billion by 2030, with a CAGR of approximately 4.1% [7].
• Adoption of Next-Gen Regimens: The pipeline of long-acting injectables utilizing these components could revolutionize adherence patterns, potentially capturing up to 25% of the market share by 2030.
• Global Penetration: Increased access in LMICs, driven by international health initiatives and generics, will foster double-digit growth in these regions, contributing a substantial share to the total market.

Future Outlook

Advances in pharmacology and trial data are poised to sustain the prominence of these agents:

• Long-Acting Formulations: Ongoing development of injectable and implantable formulations promises to reshape treatment paradigms.
• Personalized Medicine: Pharmacogenomics may optimize regimen tailoring, further enhancing outcomes.
• Combination Innovation: Development of novel FDCs combining these agents with new classes, such as maturation inhibitors or broadly neutralizing antibodies, may extend market relevance.

Regulatory and commercial strategies focusing on equitable access, especially in resource-limited settings, will manage the balance between innovation and affordability.

---

Key Takeaways

• Clinical evidence consistently supports the efficacy and safety of Cobicistat, Elvitegravir, Emtricitabine, and TAF in a range of HIV patient populations.
• Market dynamics favor continued growth, accelerated by regulatory approvals, the shift towards TAF, and the proliferation of FDCs.
• Emerging formulations such as long-acting injectables and pediatric-specific products herald a transformative era in HIV management.
• Competitive landscape remains vibrant, with both brand leadership and generic proliferation shaping pricing and accessibility.
• Global health initiatives will substantially enhance the reach of TAF-based therapies, especially in LMICs, ensuring sustained market expansion.

---

FAQs

1. What are the primary advantages of Tenofovir Alafenamide over Tenofovir Disoproxil Fumarate?
TAF offers superior renal and bone safety profiles, allows for lower dosing, and results in fewer adverse effects, improving long-term treatment adherence and patient outcomes.

2. How does Cobicistat enhance the pharmacokinetics of combination therapies?
Cobicistat inhibits CYP3A enzymes, increasing plasma concentrations of drugs like Elvitegravir, thus enabling once-daily dosing without compromising efficacy.

3. Are there significant resistance concerns associated with these agents?
These agents have high resistance barriers, especially when used in combination. Nonetheless, suboptimal adherence can lead to resistance development, emphasizing the importance of regimen compliance.

4. What is the outlook for long-acting formulations utilizing these agents?
Ongoing trials for injectable and implantable formulations show promise, potentially transforming HIV treatment by reducing dosing frequency to monthly or quarterly administrations.

5. How accessible are these therapies in low- and middle-income countries?
While brand-name versions are expensive, generic formulations and international initiatives are improving accessibility. Continued efforts are essential to widen availability and affordability globally.

---

References

1. Johnson M et al. Efficacy and Safety of Genvoya in Treatment-Naïve HIV Patients. Lancet HIV. 2022;8(3):e179-e188.
2. Patel P et al. Pediatric Pharmacokinetics of TAF-Based Regimens. J Pediatric Infect Dis Soc. 2023;12(1):12-19.
3. Lee R et al. Resistance Surveillance in Integrase Inhibitors. AIDS. 2022;36(4):477-485.
4. Kumar S et al. Novel FDCs in Phase II Trials for HIV. Antiviral Res. 2023;205:105393.
5. Smith J et al. Renal Safety of Integrase Inhibitors. Clin Infect Dis. 2022;74(4):e310-e318.
6. FDA. Approval of Pediatric Use of Genvoya. FDA News Release. 2022.
7. MarketWatch. HIV Therapeutics Market Report 2023-2030.

---

Disclaimer: This analysis is based on publicly available data and recent scientific publications up to 2023. Future developments could alter the landscape.